AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $230.15. The company's market cap stands at 407.06B, with a P/E ratio of 169.30 and a dividend yield of 2.9%.
On 2025-12-03, AbbVie(ABBV) stock moved within a range of $224.31 to $230.78. With shares now at $230.15, the stock is trading +2.6% above its intraday low and -0.3% below the session's peak.
Trading volume for AbbVie(ABBV) stock has reached 4.87M, versus its average volume of 6.24M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's per...
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Wondering if AbbVie stock is truly worth its recent buzz? You’re not alone, and we’re about to dig into whether it stacks up as a solid buy or just hype. Despi...
Analyst ratings
68%
of 31 ratingsMore ABBV News
The board of AbbVie Inc. ( ) has announced that it will be paying its dividend of $1.73 on the 17th of February, an increased payment from last year's comparabl...
In the past week, AbbVie announced that Canada's Drug Agency recommended reimbursement for SKYRIZI in ulcerative colitis and concluded pricing negotiations, exp...
On Friday, AbbVie Inc. (NYSE:ABBV) announced two updates for ulcerative colitis patients in Canada. ABBV is in positive territory. Check the market position he...
Image source: The Motley Fool. Thursday, November 6, 2025 at 4:16 p.m. ET Call participants President and CEO — Curran Simpson Chief Medical Officer — Steve Pa...
